Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-03-12 07:00 |
Biophytis : Résultats annuels 2018 et point sur le développement des activités
|
French | 244.0 KB | ||
| 2019-03-12 07:00 |
Biophytis Reports Annual 2018 Financial Results and Provides Operational Update
|
English | 151.0 KB | ||
| 2019-02-18 07:00 |
Biophytis présent à l’International Conference on Frailty & Sarcopenia Research…
|
French | 270.7 KB | ||
| 2019-02-18 07:00 |
Biophytis Announces Three Oral and One Poster Presentations at the 2019 Interna…
|
English | 197.3 KB | ||
| 2018-12-17 07:30 |
Biophytis renforce son équipe de management et poursuit son expansion aux États…
|
French | 223.0 KB | ||
| 2018-12-17 07:30 |
Biophytis strengthens its senior management team and continues its expansion in…
|
English | 245.9 KB | ||
| 2018-12-07 18:00 |
Biophytis présentera deux posters et fera un exposé oral lors de la 11ème Confé…
|
French | 218.7 KB | ||
| 2018-12-07 18:00 |
Biophytis Announces One Oral Presentation and Two Poster Presentations at the 1…
|
English | 220.4 KB | ||
| 2018-11-27 18:00 |
Biophytis to Host Key Opinion Leader Meeting on the Biology of Aging and its Ap…
|
English | 176.6 KB | ||
| 2018-11-27 18:00 |
Biophytis organise une réunion de leaders d'opinion sur la biologie du vieilli…
|
French | 201.5 KB | ||
| 2018-06-04 18:03 |
Résultats de l’Assemblée Générale Extraordinaire du 4 juin 2018
|
French | 234.9 KB | ||
| 2018-06-04 18:03 |
Results of the Extraordinary General Meeting held on June 4, 2018
|
English | 245.7 KB | ||
| 2018-05-28 18:07 |
Biophytis reçoit l’avis favorable de l’EMA pour la désignation Médicament Orph…
|
French | 242.0 KB | ||
| 2018-05-28 18:07 |
Biophytis receives favourable opinion from EMA for the Orphan Drug designation …
|
English | 233.0 KB | ||
| 2018-05-24 18:00 |
BIOPHYTIS : inclusion du premier patient dans l’étude de phase 2b SARA-INT de S…
|
French | 299.8 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
